Edition:
United Kingdom

Kissei Pharmaceutical Co Ltd (4547.T)

4547.T on Tokyo Stock Exchange

3,330JPY
21 Sep 2018
Change (% chg)

¥10 (+0.30%)
Prev Close
¥3,320
Open
¥3,320
Day's High
¥3,370
Day's Low
¥3,285
Volume
67,800
Avg. Vol
73,058
52-wk High
¥3,435
52-wk Low
¥2,660

Latest Key Developments (Source: Significant Developments)

Kissei Pharmaceutical says marketing approval for "Beova® Tablets 50mg" for treatment of overactive bladder
Friday, 21 Sep 2018 

Sept 21(Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says Kissei Pharmaceutical Co Ltd and KYORIN Holdings, Inc. <<<4569.T>>> jointly announced today that KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., received approval from the Ministry of Health, Labour and Welfare as of September 21, 2018 to market 'Beova® Tablets 50mg' for the treatment of overactive bladder.  Full Article

Kissei Pharmaceutical says change of president
Monday, 23 Apr 2018 

April 23 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it appoints Yoshio Furihata as president, to succeed Masaki Morozumi, effective June 27 .  Full Article

Kissei Pharmaceutical says rating withdrawal by R&I
Friday, 13 Apr 2018 

April 13 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says Rating and Investment Information, Inc. (R&I) withdrew the rating on the company of "A-" -R&I.  Full Article

JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it and JCR Pharmaceuticals Co Ltd <<<4552.T>>> jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia .In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin.Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed .  Full Article

UPDATE 1-ObsEva plans Swiss listing; trading debut on July 13

ZURICH, July 6 ObsEva, a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors.